KIORA PHARMACEUTICALS
Kiora is a clinical-stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases. KIO-301 is a molecular photoswitch that has the potential to restore light perception in patients with inherited and/or age-related retinal degeneration. KIO-101 is a next-generation, non-steroidal, immuno-modulatory and small molecule inhibitor of Dihydroorotate Dehydrogenase (“DHODH”) with best-in-class picomolar potency and a validated immune modulating mechanism (T cell proliferation inhibition) designed to overcome the off-target side effects and safety issues associated with DHODH inhibitors. In addition, Kiora is developing KIO-201, a modified form of the natural polymer hyaluronic acid, designed to accelerate corneal wound healing.
KIORA PHARMACEUTICALS
Industry:
Biotechnology Medical Pharmaceutical
Founded:
1998-01-01
Address:
Salt Lake City, Utah, United States
Country:
United States
Website Url:
http://www.kiorapharma.com
Total Employee:
11+
Status:
Active
Contact:
7813983811
Email Addresses:
[email protected]
Total Funding:
88.37 M USD
Technology used in webpage:
SPF Mobile Non Scaleable Content Microsoft Exchange Online IPv6 Microsoft Azure DNS Person Schema Google Google Cloud Gravatar Profiles CPanel SSL
Similar Organizations
Celator Pharmaceuticals
Celator Pharmaceuticals is a biopharmaceutical company developing therapies to treat cancer, using the drug ratio technology platform.
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Current Advisors List
Current Employees Featured
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2016-03-07 | Jade Therapeutics | Jade Therapeutics acquired by Kiora Pharmaceuticals | N/A |
Investors List
Armistice Capital
Armistice Capital investment in Post-IPO Equity - Kiora Pharmaceuticals
Ventech
Ventech investment in Series D - Kiora Pharmaceuticals
Generis Capital Partners
Generis Capital Partners investment in Series D - Kiora Pharmaceuticals
Innoven Partners
Innoven Partners investment in Series D - Kiora Pharmaceuticals
Medicis Capital
Medicis Capital investment in Series D - Kiora Pharmaceuticals
Natixis Private Equity
Natixis Private Equity investment in Series D - Kiora Pharmaceuticals
Innoven Partners
Innoven Partners investment in Series C - Kiora Pharmaceuticals
Nexus Medical Partners
Nexus Medical Partners investment in Series C - Kiora Pharmaceuticals
Ventech
Ventech investment in Series C - Kiora Pharmaceuticals
Medicis Capital
Medicis Capital investment in Series C - Kiora Pharmaceuticals
Key Employee Changes
| Date | New article |
|---|---|
| 2021-10-26 | EyeGate Pharmaceuticals Appoints Eric J. Daniels, MD, MBA, as Chief Development Officer and Closes Acquisition of Bayon Therapeutics, Inc. |
Official Site Inspections
http://www.kiorapharma.com Semrush global rank: 1.9 M Semrush visits lastest month: 11.52 K
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
